Scott SA, Fernandez ML, Kim H, et al. - Given poor long-term survival rates linked with advanced low-grade serous carcinoma (LGSC) have been reported, and uncertainties exist concerning the use of current therapies as LGSC represents a rare histotype, so, researchers analyzed practice patterns as well as management results as a component of a national initiative in order to acquire a better knowledge as well as improve the care of women with advanced LGSC through this retrospective cohort analysis undertaken in 5 Canadian referral institutions from 2000 to 2016. Overall survival (OS), progression-free survival (PFS), progression-free intervals (PFI), and time to next treatment (TTNT) were considered as outcome measures. Across institutions, the following 4 primary treatments were compared: surgery followed by chemotherapy (56%), neoadjuvant chemotherapy (NACT) followed by surgery (27%), surgery alone (9%), and surgery followed by anti-hormone therapy (4%). In 81%, the use of primary platinum/paclitaxel chemotherapy was reported. Worse PFS was experienced by those managed with NACT. Variables that showed a significant link with better OS/PFS in multivariable Cox regression analysis were: lesser residual disease, younger age, and primary peritoneal origin. Following the first relapse, no significant difference was evident in PFI and TTNT intervals in patients with relapsed disease, regardless of treatment type. Overall, existing notable variations in practice patterns across Canada were highlighted, which emphasizes the necessity for ongoing strategies to measure, assess and obtain optimal patient results for women with advanced LGSC.